Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
16.70
+0.52 (3.21%)
At close: Jul 2, 2026, 4:00 PM EDT
16.40
-0.30 (-1.80%)
After-hours: Jul 2, 2026, 7:23 PM EDT
Viatris Employees
Viatris had 30,000 employees as of December 31, 2025. The number of employees decreased by 2,000 or -6.25% compared to the previous year.
Employees
30,000
Change (1Y)
-2,000
Growth (1Y)
-6.25%
Revenue / Employee
$485,420
Profits / Employee
-$9,883
Market Cap
19.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 30,000 | -2,000 | -6.25% |
| Dec 31, 2024 | 32,000 | -6,000 | -15.79% |
| Dec 31, 2023 | 38,000 | 1,000 | 2.70% |
| Dec 31, 2022 | 37,000 | 0 | - |
| Dec 31, 2021 | 37,000 | -8,000 | -17.78% |
| Dec 31, 2020 | 45,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Teva Pharmaceutical Industries | 33,950 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
VTRS News
- 3 days ago - Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - PRNewsWire
- 5 days ago - Viatris announces VR-205 trial achieves primary endpoint - TheFly
- 5 days ago - Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PRNewsWire
- 6 weeks ago - Viatris price target raised to $22 from $17 at Barclays - TheFly
- 6 weeks ago - Viatris says FDA accepts for review NDA for MR-107A-02 - TheFly
- 6 weeks ago - U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - PRNewsWire
- 7 weeks ago - Viatris Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Viatris price target raised to $20 from $18 at Truist - TheFly